Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion

This article was originally published in The Pink Sheet Daily

Executive Summary

After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.

You may also be interested in...



10 Drug Launch Flops Of The Decade

The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.

Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus

Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.

BARDA Signs Biodefense Contracts With GSK And Soligenix

Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel